Ultrasound Device Enhances Brain Tumor Treatment

One of the biggest challenges in treating brain cancer is delivering therapeutic drugs past the blood-brain barrier, a protective shield that prevents harmful substances from entering the brain. Recent research has uncovered a promising solution involving ultrasound waves from a device implanted in a patient’s skull, potentially revolutionizing the treatment of brain cancer.

A groundbreaking study conducted by Northwestern Medicine in Chicago demonstrated that this new ultrasound technology could enable chemotherapy and immunotherapy drugs to penetrate the blood-brain barrier. The findings, published on June 6, 2024, in the journal Nature Communications, showed that the approach not only allowed drug delivery but also enhanced the immune system's ability to recognize and attack brain cancer cells.

"This is the first instance in humans where an ultrasound device has been utilized to deliver drugs and antibodies to glioblastoma, altering the immune system’s response to recognize and combat brain cancer," said Dr. Adam Sonabend, an associate professor of neurological surgery at Northwestern University Feinberg School of Medicine. Sonabend emphasized that this could be a significant advancement in treating glioblastoma, a notoriously difficult cancer to manage due to the poor penetration of drugs and antibodies into the brain.

The study involved four patients with advanced brain cancer, who had previously undergone chemotherapy and participated in an experimental clinical trial, but both efforts had failed to prevent the recurrence of their tumors. These patients received an implant that emits ultrasound waves to create "microbubbles," temporarily opening the blood-brain barrier. Through these microbubbles, a small dose of the chemotherapy drug doxorubicin, combined with antibodies, was delivered to the brain to enhance the immune system's detection and attack of cancer cells.

This innovative combination boosted the recognition of cancer cells and reinvigorated the immune cells responsible for attacking and eliminating tumors. "Given the ineffective immune response against these deadly tumors, our findings encourage us to consider a novel treatment approach," stated researcher Catalina Lee-Chang, an assistant professor of neurological surgery at Northwestern.

Looking ahead, researchers are planning a follow-up clinical trial to initially treat ten brain cancer patients to assess safety, followed by another 15 patients to evaluate the treatment’s effectiveness. Historically, large clinical trials have not demonstrated that immunotherapy can prolong survival in brain cancer patients. However, Sonabend is optimistic that the treatment could be effective if antibodies and drugs can enter the brain more efficiently.

"In this small cohort of patients, we show that using this technology can enhance the delivery of chemotherapy and antibodies, altering the tumor’s microenvironment so that the immune system can recognize the tumor," Sonabend said.

This pioneering research opens new avenues for treating glioblastoma and potentially other brain cancers, offering hope for more effective and targeted therapies in the future.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!